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EDITORIAL REVIEW
Variable expression of major histocompatibility antigens:
Role in transplantation immunology
In experimental studies, many factors have been identified
which play a role in the long—term survival of grafts of organs
and tissues. The relative importance of these factors in clinical
transplantation is largely unknown. It is not clear why, in the
early period after transplantation, high doses of immunosup-
pressants are required to prevent graft rejection, while at later
stages these drugs can be lowered in dosage or, in some
patients, even completely discontinued. Explanations based on
changes in the immune response of the host have initially
received much attention. Tolerance by deletion of specific
antigen—reactive cells, blockade of the response by specific
alloantibodies, or by the emergence of suppressor cells have all
been identified as possible mechanisms. In these studies the
graft was generally regarded as a more or less static target for
the effector mechanisms of the host. More recently, it was
realized that the graft itself is also subject to changes which may
play a decisive role. First, the passenger cell concept has
regained new interest with the emergence of new data on the
role of antigen presenting cells, especially dendritic cells, and
the notion that these cells are bone marrow—derived and are
gradually replaced by host cells after transplantation. Secondly,
there are now several lines of evidence that the antigenic make
up of resident cells in the graft is also subject to considerable
variations. It is the variability in the expression of major
histocompatibility antigens (MHC antigens) that will be dealt
with in this review. Data both from in vitro and in vivo studies
will be discussed, and subsequently we will make an attempt to
delineate their relevance for clinical transplantation.
Basal expression of class 1 and class II antigens in different
tissues
MHC antigens are present on the cells of all vertebrates.
Most information on their expression has been obtained from
studies in mice, rats, and man, and thus far the cell and organ
distributions of these antigens have shown a remarkable homol-
ogy among the different species. The MHC antigens can he,
divided into two distinct classes of molecules. Class I antigens
consist of a 45,000 dalton polypeptide heavy chain that is
anchored in the cell membrane, and is non-covalently associ-
ated with a smaller polypeptide chain of 12,t)00 dalton, /3-2-
microglobulin. In man, the heavy chain is coded for by genes on
the HLA-A, B, and (2 loci of the MHC on chromosome 6, while
3-2-microglobulin is coded for on chromosome 15. Class II
antigens consist of two glycoprotein chains of 34,000 and 29,000
Received for publication May 22, 1985,
and in revised form October 28, 1985
© 1986 by the International Society of Nephrology
1
daltons, both anchored in the cell membrane. In man they are
coded for by genes in the D region of the MHC.
The expression of class I antigens gradually develops during
fetal life. In the adult, these antigens have been demonstrated
on the surface of most nucleated cells, with variations in the
basal amounts of antigen expressed in different tissues. In
stainings of tissues with monoelonal antibodies against class I
antigens of rats and man, low to negative expression has been
found on the nervous tissue of the brain, on skeletal and cardiac
muscle cells, on hepatocytes, and on endocrine cells [1, 21. In
human tissues, Daar et at additionally found no expression of
class I antigens on villous trophoblast, mature spermatozoa,
corneal endothelium, and some exocrine glandular cells 11].
High levels of class I antigens are usually found on cells of the
immune system [31. Reported differences in the expression of
MHC antigens on tissues of different species are not easy to
interpret because of differences in technical approaches, and
differences in the specificities and affinities of conventional or
monoelonal antibodies used to detect the antigens. With regard
to the kidney, there is general agreement that class I antigens
are present on endothelial cells of all vessels and on interstitial
cells in rats [2, 4—6], mice [7], and man [1, 8—10]. Most authors
also agree that the class I antigens are normally expressed on
renal tubular epithelium in man [1, 8—10] and rats [4].
Unlike the nearly ubiquitous presence of class I antigens, the
class II antigens have a more restricted distribution. They have
primarily been described on cells involved in immune reactions.
Their concentration is very high on dendritic cells and
Langerhans cells, and moderate to low on B cells. On cells of
the monocyte—macrophage lineage, the expression ranges from
high in some cells to low in other ones. A low MHC class II
antigen expression is observed in neonates, Macrophages from
neonatal mice express class II antigens on a reduced number of
cells [11] and a similar finding was reported for human cord
blood monocytes [12]. More recently, class II antigens have
also been detected on non-bone marrow—derived cells, although
studies in different tissues in various species have shown dis-
crepancies. Quantitative studies on the distribution of class 11
antigens on renal tissue of the rat by Hart en Fabre [13] and on
human kidney by Williams et at [3] showed that the renal tissue
of both species contained surprisingly high amounts of class 11
antigen, while in normal mouse kidney the expression of Ia
antigens was found to be rather low, both in quantitative
absorptions [14] and in morphologic studies [15, 16]. Histologic
studies on the localization of class II antigens in renal tissue of
man have demonstrated these antigens on the endothelial cells,
especially those of the glomerulus and peritubular capillaries.
They are also present in the mesangium and on dendritic cells of
the peritubular interstitium [8, 10, 17—19]. In the rat kidney the
mesangial cells expressing these antigens have been identified
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as phagocytic cells [20, 21]. In rodents the endothelial cells in
normal kidneys are generally considered not to express class II
antigens [4, 6, 15, 22]. The renal tubular epithelium has been
found negative for class II antigens in normal kidneys of mice
[15, 23], but positive in those of rats [4, 6, 221 and man [8, 10,
24]. This expression was usually weak and patchy with a
preferential localization in the proximal tubuli. In most studies
it was found that the class II antigens were present not on the
cell membrane, but in the cytoplasm of the proximal tubular
cells [8, 10, 16, 22]. This has even led to the speculation that the
antigens have a special function here in the transport of mac-
romolecules reabsorbed from the urine. However, Mayrhofer
and Schon—Hegrad have found that with appropriate fixation,
class II antigens in rat kidney are demonstrable on the lateral
and basal cell membranes of the proximal convoluted tubules
[61. It is likely that the intracellular location was based on an
artifact. The membranous localization is better in line with the
concept that the class II molecules play a role in antigen
presentation. In a study on the distribution of class II antigens
in 46 normal human kidneys, Fuggle et al [10] found a positive
staining of the proximal tubuli in only 60% of the renal biopsies,
and weak to negative staining in the remaining cases. It seems
that, apart from species differences, there may be physiological
fluctuations in the "basal" expression of Ia antigens on dif-
ferent cells. This is consistent with the accumulating evidence
that the class II expression in many cells is variable and
strongly related to the presence of immunologic stimuli.
Variability of MHC antigen expression in vitro
It was already recognized in 1973 by Lindahl and coworkers
[251 that the expression of mouse leukocyte cell surface anti-
gens was enhanced in vitro by interferon. At that time, neither
the nature of the surface antigens nor the composition of the
interferon preparation was exactly known, although it was
suspected that in particular the expression of MHC antigens
was influenced. In the following years it became clear that
MHC antigen expression varied in vitro on several types of
cells. Murine T cells became class II positive after activation by
concanavalin A (Con A) and also after antigen—induced prolif-
eration [26, 27]. These antigens were not acquired by transfer
from other cells, but were synthesized by the T cells them-
selves. Murine macrophages could be induced to express class
11 molecules in vitro as well [28]. For this expression a soluble
mediator was required that was released by activated T lym-
phocytes [29]. Similarly, increased expression of both class I
and class II antigens has been induced on cultured neonatal
mouse kidney cells by supernatants of lymphocytes stimulated
with Con A [7]. Induction of class II antigen expression was
observed also on cultured vascular endothelial cells, after
stimulation with phytohemagglutinin (PHA) [30], and on human
cultured follicular thyroid cells after stimulation with several
lectins [31]. More detailed studies became possible after the
development of highly specific, monoclonal antibodies against
MHC determinants, and after the introduction of recombinant
DNA techniques for the synthesis of pure interferons. Since
1982, numerous studies have been reported in which the effect
of recombinant interferon-y (IFN-y) on various cell types was
investigated and compared with the effects of IFN-a and
IFN-/3. It was found that IFN-y was the most potent inducer of
both class I [32—371 and class II antigens [33—35, 38—46]. IFN-a
and IFN-p also enhance the expression of class I antigens on
various cell types but seem to be ineffective in enhancing class
II expression [32, 36, 37, 42—44, 46, 47].
It is largely unknown how interferons enhance antigen
expression at the molecular level. It has been found that
induction or enhancement by IFN-y is always accompanied by
an accumulation of cytoplasmatic messenger RNA (mRNA) for
the antigens to be expressed, followed by increased biosynthe-
sis of the MHC product [44, 48—50]. Elevation of intracellular
calcium levels and activation of protein kinase activity may be
involved [51]. In the above—mentioned studies it was observed
that in certain cell types, IFN-y induced a de novo transcription
of previously silent MHC genes [36, 481. On the other hand, it
was found that the amount of mRNA already present and the
levels of antigen expression could further be increased by
IFN-y [44, 48], suggesting that IFN-y has both inducing and
modulating capacity. It is interesting in this respect that cells
normally expressing class I antigens at a certain level may
completely loose these antigens in a serum—free environment
[37]. Also, macrophages in culture show a gradual decline in the
expression of class II antigens [521, and this can be reversed by
the addition of IFN-y [38] or fresh homologous T cells [531.
These findings suggest that a continuous presence of the induc-
ing agent is required to maintain MHC antigen expression.
The activity of IFN-y is antagonized by several agents.
Prostaglandins El and E2 [54], c-fetoprotein [55], and cortico-
steroids [56] inhibit class II antigen expression on cultured
mouse macrophages, even in the presence of IFN-y. Agents
inducing prostaglandin production, such as lipopolysaccharides
[57] or certain immune complexes [58] are also able to inhibit
IFN-y induced class II expression in macrophages.
Some other agents can induce MHC expression in vitro, such
as lectins [31, 59], sodium butyrate [36], and calcitriol [37]. A
direct action of these agents has not been proven. They may all
act via induction of IFN-y synthesis.
The activating effects of interferons are not specific for MHC
induction. The synthesis of other proteins, such as Fe receptors
[60, 61], tubulin [62], and fibronectin [631 is also increased in the
presence of IFN-y and various cell functions are stimulated
[64]. These aspects, as well as the question which cells and
stimuli are responsible for interferon production, are beyond
the scope of this review.
Variability of class I and class II MHC antigen expression
in vivo
In 1980, Klareskog, Forsum, and Peterson [65] reported that
in mammary glands of guinea pigs and mice class II antigen
expression could be induced in the epithelial cells by pregnancy
and lactation, and also by administration of lactotropic hor-
mones. The authors noted that this expression of Ia-like anti-
gens occurred simultaneously with the accumulation of
lymphoid cells in the gland. Soon after this report, Lampert,
Suitters, and Chisholrn [66] described the induction of Ia
antigens on epidermal keratinocytes in rats during graft versus
host disease (GVHD), while simultaneously Mason, Dailman,
and Barclay [67] demonstrated that GVHD induced class II
antigen expression in both epidermal cells and gut epithelium of
the rat. They suggested that this expression, arising under
immunologic stimulation, might be an indication for a function
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of these class II determinants in inflammatory and autoimmune
diseases. In the following years this hypothesis was corrobo-
rated by studies demonstrating that not only GVHD, but also
other allogeneic [68, 691 and non-allogeneic stimuli, such as
contact hypersensitivity [70], could induce Ia expression on
epidermal keratinocytes, while trichinella infection was accom-
panied by the expression of class II antigens in gut epithelium
[71]. In 1983 we reported that in mouse skin allografts the
process of rejection was accompanied by the appearance of
considerable amounts of Ia antigen on the murine endothelium,
which normally does not express these antigens in demonstra-
ble quantities [72]. This expression on endothelial cells proved
to be dependent on the immunologic status of the recipient, and
could be prevented by treatment with Cyctosporin A or by the
use of congenitally athymic recipients. Increased expression of
both class I and class II antigens on endothelial cells in cell
suspensions obtained by fine needle aspirates of human renal
allografts was first reported by Hhyry et al [73], who related this
finding to the occurrence of repeated rejection episodes.
Simultaneously with the more or less controversial reports on
the presence or absence of basal class II antigen expression on
renal tubular epithelium in different species, several studies
were published demonstrating that considerable amounts of
class II antigens could be induced on human and mouse renal
tubular cells during the process of alloreactive stimulation or
rejection [15, 741 or in non-transplanted murine kidneys during
GVHD [7, 16, 751. Further evidence for the in vivo effect of
allogeneic stimulation on the expression of MHC antigens in
graft tissue was obtained by Milton and Fabre [76], who
reported a massive induction of both class I and class II
antigens in rejecting cardiac allografts in rats. In all these
studies the induced or increased expression of either class I or
class II antigens has been proven to be of donor origin, which
implies that these antigens are not acquired from an extracel-
lular source but are intracellularly produced by the expressing
cells.
Several clinical studies suggest that an increased expression
of class II antigens occurs in autoimmune diseases. One is the
finding of Hanafusa et al that the expression of class II MHC
antigens on human thyroid epithelium is markedly increased in
autoimmune thyroiditis [77, 78]. Another example is the in-
creased expression of HLA-DR antigens on human bile duct
epithelium in patients with primary biliary cirrhosis, while bite
ducts in normal liver do not express these antigens [791.
In general, in these and other studies attention has been
focused on the variable expression of class II determinants
only. One reason for this special interest is no doubt the
intriguing discrepancy between the restricted "basal" expres-
sion of these antigens in normal, unstimulated cells and the
increased expression after stimulation, with its possible impli-
cations for immunologically induced disease. Another factor
might be that variations in the expression of class I antigens are
more difficult to demonstrate, The technical procedures mostly
applied involve staining of cryostat tissue sections with mono-
clonal antibodies. With these procedures, one can easily dem-
onstrate the appearance of antigens that are not present in
control sections, while this staining procedure is not appropri-
ate for the quantitative measurement of variations in antigenic
expression of determinants that are already present on virtually
all normal cells. Despite this difficulty, several authors mention
an increase in the expression of class I antigens under similar
conditions that induce class II antigens in various tissues. In
this respect the study of Appleyard ct al [80] is of interest,
which describes an increase of class I antigens in human muscle
cells in patients with inflammatory muscular diseases, consist-
ent with an earlier report on patients with polymyositis [81]. A
similar increase in class I antigen expression (in part together
with class II expression) has also been found in autoimmune
thyroiditis [77], in several forms of hepatitis [82] and eholangitis
[791, in hepatocytes of liver allografts [83], and, furthermore, as
already mentioned, in renal tubular cells of kidneys during
GVHD [7], in rejecting kidney allografts [731, and in muscle
cells in cardiac gratis [76]. The variable expression of MHC
antigens on non-bone marrow derived cells may also he impor-
tant in the field of oncology. Both increases and decreases of
class I and class II antigens have been found in several ma-
lignant tumors [841.
The mechanism of induction of increased biosynthesis of
MHC antigens on non-bone marrow—derived cells, which nor-
mally do not carry substantial amounts of these antigens, is not
known. During GVHD, tubular cells of mouse kidneys were
found to produce increased amounts of class 11 mRNA [85] in
accordance with the earlier mentioned results of in vitro studies
with IFN-y. The factors that influence MHC antigen expression
in vivo are thought to he at least partly the same as those
operating in vitro. Treatment of mice with interferon resulted in
increased expression of MHC antigens on thymic and splenie
lymphocytes [86], but a direct demonstration of the role of
interferon in MHC induction as a result of an inflammatory
process is lacking. It is also not clear whether the increased
expression of class II antigens in the mammary gland under the
influence of lactotropic hormones is the result of a direct action
of these hormones on the epithelial cells or is mediated by
proliferation of lymphoid cells and/or concomitant interferon
synthesis.
As mentioned earlier, a low MHC class II antigen expression
is observed in neonates. Investigation in mice showed that this
low expression might be caused by a high synthesis of prosta-
glandin E [87], or, additionally, by the presence of a-fctoprotein
[55]. In man, the phenomenon might be related to a limited
ability of fetal blood leukoeytes to produce IFN-y [88], which
seems to be due to a high sensitivity to prostaglandin E [89].
Functional role of the variable expression
Immune response and MHC restriction
The basic physiological function of MHC antigens is to guide
the recognition of foreign antigens. T cells recognize foreign
antigens only in the context of their own MHC molecules. This
phenomenon is called MHC restriction. Thus, in the efferent
arm of the immune response, specific cytotoxie T cells can only
recognize cells bearing viral or tumor antigens if two conditions
are fulfilled: 1) they have to share class I molecules with the
target cells; and 2) these same molecules must have been also
present on the cells that initiated the immune response. Class II
molecules regulate the recognition in the afi'erent arm of the
immune response in a similar manner. T helper cells recognize
foreign antigen on antigen presenting cells only if they share
class II molecules with these cells. The class II molecules also
regulate the interaction between T helper cells and B cells. How
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the combined recognition takes place is not clear. Two main
concepts have been proposed. One is that association of the
antigen with the MHC molecule results in a new antigenic
determinant that is recognized by a single receptor on the T cell
(altered self). The other concept assumes a cooperation of two
separate receptors, one of which recognizes the antigen while
the second is specific for self-MHC (dual recognition).
The release of mediators during an immune response in-
creases the expression of MHC antigens. This will facilitate the
MI-IC-restricted recognition and the elimination of foreign an-
tigens in a positive feedback loop [90]. In the resulting inflam-
matory reaction, there is also induction of MUC antigens on
non-lymphoid cells that do not carry detectable amounts of
MHC antigens in the quiescent stage. It is likely that these cells
will subsequently become involved in the immune reaction.
Thus, endothelial cells can function as antigen presenting cells
in vitro, and this is linked to their class II expression [91].
Similarly, mouse fibroblasts can acquire antigen presenting
capacity after gene transfer of class It genes [92]. There is
evidence that an increased expression of class I antigens makes
tumor cells more sensitive to MHC-restricted cell—mediated
lysis [84].
Increased or aberrant MHC expression occurs in several
auto-immune diseases both in animals [93] and man [77, 79, 801.
Botazzo et al have suggested that local aberrant expression of
class II antigens may evoke an auto-immune inflammatory
process [78, 94]. The initiating event could be the local produc-
tion of IFN-y or other stimulators of MUC expression caused
by viral infection [95]. This is in keeping with experimental
studies, demonstrating that treatment with IFN-y causes accel-
erated progression of auto-immune discase in NZB-mice [961.
Conversely, a decreased expression of MHC probably also
has important consequences for the immune response. The low
expression during fetal and neonatal life may be important for
the development of tolerance to self-antigens [53]. Also, a loss
of expression of MHC antigens on tumor cells may enable these
cells to escape from the normal immune surveillance mecha-
nisms [84].
Immune response to MHC antigens
In contrast to the recognition of non-MHC molecules, the
response to foreign class I or class II antigens is not MHC-
restricted. T cells can interact directly with cells carrying
allogeneic MHC antigens. Presentation of these antigens on
syngeneic host cells is not necessary for the recognition. This
explains why MHC incompatibilities form the major barrier to
successful transplantation of organs and tissues. Allogeneic
class I antigens can serve as targets for cytotoxic T cells or
destructive antibodies. Cell—mediated damage of class II hear-
ing targets can also be effected by cytotoxic T cells [97].
Recently, it has been proposed that delayed type hypersensi-
tivity exerted by T helper cells which recognize class 11
determinants plays an important role in graft rejection [981.
These cells do not directly mediate destruction, but by produc-
ing lymphokines they attract inacrophages to the graft site,
which become activated and can subsequently destroy the
graft. Studies are currently being carried out in several labora-
tories to define the respective roles of cytotoxic T cells and T
helper cells in graft rejection [99, 100]. Although antibodies
against class II antigens can lyse cells carrying the correspond-
ing antigens in vitro in the presence of complement, there is no
good evidence that they can cause graft damage. In experimen-
tal situations, they can even prolong graft survival, a phenom-
enon termed immunologic enhancement [101, 102]. It is not
clear whether these antibodies are destructive, protective, or
harmless in clinical transplantation [103]. The ultimate effect
probably depends on the concentration of class II antigens on
the vascular endothelium, which is the primary target for
antibody—mediated damage.
It seems obvious that a decreased expression of MUC
antigens in a graft makes it less susceptible to rejection, Such a
decrease can occur in two different ways: 1) disappearance
from the graft of cells carrying donor MHC antigens; and 2)
decreased expression of MHC antigens on resident cells.
Class II antigens, expressed on cells primarily involved in
antigen presentation (dendritic cells, macrophages) are of major
importance in the recognition phase of the allograft response.
These cells are bone marrow—derived and are gradually re-
placed by their counterparts of host origin after transplantation,
making the graft less immunogenic. Removal of these so—called
passenger cells before transplantation has led to prolonged graft
survival in several experimental models. The most impressive
results have been achieved with thyroid grafts and islets of
Langerhans from which the passenger cells were removed by
culture in vitro before transplantation [104, 105]. The prolonged
and often indefinite survival that followed was not caused by a
loss of antigenic targets in the grafted tissues, since the grafts
were rejected when the recipients were challenged with donor
lymphoid cells [106, 107]. Prolonged survival can also be
obtained by pretreatment of islets with antibodies against class
U antigens or against dendritic cells in the presence of comple-
ment [108, 109]. The prolonged survival of rat kidney grafts,
which has been found in some strains after retransplantation of
long surviving grafts into second hosts, has also been attributed
to the disappearance of passenger cells [110, III]. However,
attempts to prolong survival of skin gratis by removal of
passenger cells have consistently failed [112]. This is probably
caused by the induction of class!! expression on resident cells,
such as endothelial cells, that can subsequently serve as
stimulatory cells.
The second way iu which the graft can escape from rejection
is by a decreased expression of MHC antigens on its resident
cells. This concept can provide a more acceptable explanation
for the phenomenon of graft adaptation, which is defined as a
decrease in vulnerability of the graft to an already established
immune response [1131. Adaptation has been most extensively
studied in murine skin graft models. In these models it can be
shown that there is a decreased sensitivity of long standing
grafts not only to cell—mediated [114, 115], but also to anti-
body—mediated [116] damage. The latter model is well suited for
further analysis of the phenomenon. Allogeneic skin grafts
become less sensitive to the destructive action of intravenously
injected antidonor alloantibody after prolonged residence on
the recipient. After retransplantation onto recipients isogencic
to the original ones, long standing grafts regain their high
sensitivity. It is likely that the retransplantation procedure, with
its concomitant inflammatory reaction, stimulates the expres-
sion of the MHC antigens. Milton and Fabre have shown that
even the transplantation of isografts of heart and kidney induces
an increase of the expression of class I antigens [76]. A de-
MHC antigens in transplantation immunology 5
creased expression of MHC antigen as an explanation for the
development of graft adaptation is in keeping with our finding of
decreased binding of labelled monoclonal anticlass I and
anticlass II antibody to the donor endothelium after prolonged
residence of the graft, and the reappearance of high binding if
rejection of the graft is allowed to occur by withdrawal of
immunosuppression 72, unpublished observations].
Relevance for clinical transplantation
An increased expression of class II antigens may be a useful
indicator for incipient rejection in clinical transplantation [74].
This must be further evaluated, especially the expression of
class II antigens on renal tubular cells obtained by fine needle
aspirates of the grafts. it seems also worthwhile to investigate
whether tubular cells appearing in the urine can be stained for
class II antigens. This could furnish a simple non-invasive
diagnostic test for rejection. Measurement of class II expres-
sion may also be useful to distinguish between Cyclosporin A
induced nephrotoxicity and graft rejection, since it has been
demonstrated that Cyclosporin A suppresses the expression of
class II antigens on renal tubular cells in the rat [117].
Since interferons are the strongest inducers of MDC anti-
gens, it can be expected that treatment with interferon may
trigger graft rejection. Indeed a recent report in which high
doses of IFN-a were used as a prophylaxis to viral infections in
renal transplant recipients, suggests that this may occur. Soon
after transplantation all patients developed severe, biopsy—
proven rejections, resistant to steroids and only reversible by a
course of antithymocyte globulin [118]. Although the triggering
mechanism may have been increased MHC expression, other
possibilities, such as direct augmentation of the host's immune
response by interferon, cannot be excluded [64].
It has been repeatedly suggested that viral infections are
associated with graft rejection [119—1211. Increased levels of
interferon have been found in sera of patients with viral
infections [122] and also, interestingly, in sera of patients and
animals with auto-immune disorders [641. One of the possible
mechanisms by which viral infection triggers rejection is by an
interferon—mediated increase of the expression of MHC-an-
tigens. The infection most frequently implicated is that caused
by cytomegalovirus (CMV). On the basis of a prospective
study, Marker et al concluded that CMV infection was respon-
sible for 20% of renal graft failures [1211. Also, chronic GVHD
was significantly more common in bone marrow transplant
patients who had experienced CMV infections, and in all these
cases, the infection preceded the onset of GVHD 11231.
Is there any indication that a decreased expression of MHC
antigens provides some form of protection to the graft or that a
phenomenon similar to adaptation occurs in clinical transplan-
tation? Differences in expression of MHC antigens may explain
why liver grafts are less susceptible to rejection than grafts of
other organs [124]. In pancreatic transplantation, the passenger
cell concept may have great potential. Removal of class II
antigen bearing passenger cells from pancreatic islets should
theoretically he feasible in man, but thusfar attempts have not
been successful 1125]. Adaptation is difficult to study in hu-
mans. We have reported a clinical case in which a graft partially
escaped from an ongoing immune response [1261. A patient who
had received a renal graft with two arteries, one of which had
become stcnotic, developed a chronic vascular rejection which
led to removal of the graft. The kidney showed diffuse rejection
glomerulopathy, except for the poststenotic segment in which
only signs of isehemia were seen. Although circulating anti-
donor antibodies were demonstrable in the serum of the patient,
there were no deposits of immunoglobulin in the poststenotic
segment, in contrast to diffuse and abundant deposition in the
rest of the kidney. Although the evidence is indirect, this finding
could be explained by a decreased expression of target antigens
in the segment with low perfusion.
in conclusion, the expression of MHC antigens is character-
ized by such a great variability and inducibility that the concept
of a "basal" expression becomes an academic one. Some form
of stimulation seems to he always required, and in its complete
absence levels tend to fall to zero in many, if not all, cells and
tissues. In the normal physiologic situation the final level of
expression is determined by a dynamic equilibrium between
stimulatory and inhibitory factors. The clearly established
increased expression of MHC antigens during rejection epi-
sodes and the indications for a decrease to normal in established
grafts make it likely that the variability of antigen expression
plays a role in determining the ultimate fate of the graft. The
active research that is now going on in this field will certainly
give us a better insight in the role that this variability plays, and
will possibly also provide us with new tools to control the
allograft reaction.
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